A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial - 30/10/18
Doi : 10.1016/j.ahj.2018.07.002
Sandra Korol, BSc a, b, Michel White, MD a, c, ⁎ 
, Eileen O’Meara, MD a, c, François Tournoux, MD, PhD d, Normand Racine, MD a, c, Anique Ducharme, MD, MSc a, c, Jean-Lucien Rouleau, MD a, c, Mark Liszkowski, MD a, c, Asmaa Mansour, MSc e, Martin Jutras, BSc b, Marie-Claude Guertin, PhD e, Mathieu Bernier, MD f, Joël Lavoie, PhD a, Grégoire Leclair, BPharm, PhD b, Paul-Eduard Neagoe, PhD a, Diana Chaar, MSc a, c, Martin G. Sirois, PhD a, c, Simon de Denus, BPharm, MSc, PhD a, b, ⁎⁎
, Eileen O’Meara, MD a, c, François Tournoux, MD, PhD d, Normand Racine, MD a, c, Anique Ducharme, MD, MSc a, c, Jean-Lucien Rouleau, MD a, c, Mark Liszkowski, MD a, c, Asmaa Mansour, MSc e, Martin Jutras, BSc b, Marie-Claude Guertin, PhD e, Mathieu Bernier, MD f, Joël Lavoie, PhD a, Grégoire Leclair, BPharm, PhD b, Paul-Eduard Neagoe, PhD a, Diana Chaar, MSc a, c, Martin G. Sirois, PhD a, c, Simon de Denus, BPharm, MSc, PhD a, b, ⁎⁎ a Montreal Heart Institute, Montreal, QC, Canada
b Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada
c Faculty of Medicine, Université de Montréal, Montreal, QC, Canada
d Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada
e Montreal Health Innovations Coordinating Center, Montreal, QC, Canada
f Quebec Heart and Lung Institute, Quebec, QC, Canada
⁎Reprint requests: Michel White, MD, Montreal Heart Institute, 5000 Bélanger, Montreal, Quebec, H1T 1C8, Canada.Montreal Heart Institute5000 BélangerMontrealQuebecH1T 1C8Canada⁎⁎Reprint requests: Simon de Denus, BPharm. MSc, PhD, Montreal Heart Institute, 5000 Bélanger, Montreal, Quebec, H1T 1C8, Canada.Montreal Heart Institute5000 BélangerMontrealQuebecH1T 1C8Canada
Abstract |
Mineralocorticoid receptor antagonists (MRAs) decrease morbidity and mortality in patients with heart failure (HF). However, spironolactone, a non-selective MRA, has been shown to exert a harmful effect on glucose homeostasis. The objective of this multicenter, randomized, controlled, double-blind trial was to compare the effects of spironolactone to those of the selective MRA eplerenone on glucose homeostasis among 62 HF patients with glucose intolerance or type II diabetes.
Trial registration number:NCT01586442.
Le texte complet de cet article est disponible en PDF.Plan
| RCT# NCT01586442. |
© 2018
Elsevier Inc. Tous droits réservés.
Vol 204
P. 190-195 - octobre 2018 Retour au numéro
Article précédent
- The National Echocardiography Database Australia (NEDA): Rationale and methodology
- Geoff Strange, David S Celermajer, Tom Marwick, David Prior, Marcus Ilton, Jim Codde, Gregory M Scalia, Simon Stewart, Max Bulsara, Eli Gabbay, David Playford
- Management of cardiogenic shock in acute decompensated chronic heart failure: The ALTSHOCK phase II clinical trial
- Nuccia Morici, Fabrizio Oliva, Silvia Ajello, Miriam Stucchi, Alice Sacco, Manlio Gianni Cipriani, Michele De Bonis, Andrea Garascia, Maria Pia Gagliardone, Giulio Melisurgo, Claudio Francesco Russo, Carlo La Vecchia, Maria Frigerio, Federico Pappalardo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?